+Compare
KURA
Stock ticker: NASDAQ
AS OF
Loading...
Price
Loading...
Change
Loading...
Capitalization
670.35M

KURA Kura Oncology Forecast, Technical & Fundamental Analysis

a provider of biopharmaceutical services

Industry Biotechnology
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
A.I.Advisor
a Summary for KURA with price predictions
08:00 PM EDT Sep 21, 2023

KURA's RSI Indicator is staying in oversold zone for 2 days

It is expected that a price bounce should occur soon.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where KURA advanced for three days, in of 281 cases, the price rose further within the following month. The odds of a continued upward trend are .

KURA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on September 11, 2023. You may want to consider selling the stock, shorting the stock, or exploring put options on KURA as a result. In of 80 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for KURA turned negative on August 22, 2023. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 40 similar instances when the indicator turned negative. In of the 40 cases the stock turned lower in the days that followed. This puts the odds of success at .

KURA moved below its 50-day moving average on August 22, 2023 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for KURA crossed bearishly below the 50-day moving average on August 30, 2023. This indicates that the trend has shifted lower and could be considered a sell signal. In of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where KURA declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for KURA entered a downward trend on September 22, 2023. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

Fear & Greed

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.458) is normal, around the industry mean (22.655). P/E Ratio (0.000) is within average values for comparable stocks, (131.527). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.920). Dividend Yield (0.000) settles around the average of (0.034) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (308.747).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. KURA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. KURA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 96, placing this stock worse than average.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Moderna (NASDAQ:MRNA), Incyte Corp (NASDAQ:INCY), Sarepta Therapeutics (NASDAQ:SRPT), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), BioCryst Pharmaceuticals (NASDAQ:BCRX), Adaptive Biotechnologies Corp (NASDAQ:ADPT), Novavax (NASDAQ:NVAX), Sorrento Therapeutics, Inc. (OTC:SRNEQ).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.18B. The market cap for tickers in the group ranges from 402 to 410.6B. NVO holds the highest valuation in this group at 410.6B. The lowest valued company is PNEXF at 402.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -5%. For the same Industry, the average monthly price growth was 32%, and the average quarterly price growth was 32%. SKYED experienced the highest price growth at 81%, while SEEL experienced the biggest fall at -82%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was -27%. For the same stocks of the Industry, the average monthly volume growth was 80% and the average quarterly volume growth was 85%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 87
Price Growth Rating: 69
SMR Rating: 93
Profit Risk Rating: 95
Seasonality Score: -26 (-100 ... +100)
View a ticker or compare two or three
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
A.I. Advisor
published Earnings

KURA is expected to report earnings to rise 2.60% to -54 cents per share on November 08

Kura Oncology KURA Stock Earnings Reports
Q3'23
Est.
$-0.54
Q2'23
Beat
by $0.01
Q1'23
Beat
by $0.04
Q4'22
Beat
by $0.08
Q3'22
Beat
by $0.01
The last earnings report on August 03 showed earnings per share of -52 cents, beating the estimate of -54 cents. With 391.15K shares outstanding, the current market capitalization sits at 670.35M.
A.I. Advisor
published General Information

General Information

a provider of biopharmaceutical services

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
12730 High Bluff Drive
Phone
+1 858 500-8800
Employees
133
Web
https://www.kuraoncology.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
BRXVX11.650.05
+0.43%
MFS Blended Research Intl Eq R6
ATEZX132.970.20
+0.15%
AB Sustainable Global Thematic Z
TANDX33.11-0.04
-0.12%
Castle Tandem Institutional
GGECX17.36-0.03
-0.17%
Nationwide Global Sust Eq C
PCCOX42.35-0.07
-0.17%
T. Rowe Price U.S. Equity Research I

KURA and

Correlation & Price change

A.I.dvisor indicates that over the last year, KURA has been loosely correlated with ALLO. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if KURA jumps, then ALLO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To KURA
1D Price
Change %
KURA100%
-1.88%
ALLO - KURA
43%
Loosely correlated
-1.88%
KROS - KURA
43%
Loosely correlated
-0.48%
SWTX - KURA
42%
Loosely correlated
-1.74%
AXON - KURA
41%
Loosely correlated
-0.36%
XNCR - KURA
40%
Loosely correlated
-0.93%
More

Groups containing KURA

Correlation & Price change

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To KURA
1D Price
Change %
KURA100%
-1.88%
biopharmaceuticals
(undefined stocks)
41%
Loosely correlated
-0.37%
drugs
(undefined stocks)
38%
Loosely correlated
-0.89%
biotechnology
(undefined stocks)
33%
Loosely correlated
-0.81%